Form 8-K

8-K — Apimeds Pharmaceuticals US, Inc.

Accession: 0001213900-26-092680

Filed: 2026-08-21

Period: 2026-08-19

CIK: 0001894525

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — ea0303076-8k_apimeds.htm (Primary)

EX-10.1 — ASSIGNMENT AND TRANSFER AGREEMENT OF CERTAIN APITOX RIGHTS, DATED AUGUST 19, 2026, BY AND BETWEEN APIMEDS PHARMACEUTICALS US, INC. AND FREET INC (ea030307601ex10-1.htm)

GRAPHIC (ea030307601_ex10-1img1.jpg)

GRAPHIC (ea030307601_ex10-1img2.jpg)

GRAPHIC (ea030307601_ex10-1img3.jpg)

GRAPHIC (ea030307601_ex10-1img4.jpg)

GRAPHIC (ea030307601_ex10-1img5.jpg)

GRAPHIC (ea030307601_ex10-1img6.jpg)

GRAPHIC (ea030307601_ex10-1img7.jpg)

GRAPHIC (ea030307601_ex10-1img8.jpg)

GRAPHIC (ea030307601_ex10-1img9.jpg)

GRAPHIC (ea030307601_ex10-1img10.jpg)

GRAPHIC (ea030307601_ex10-1img11.jpg)

GRAPHIC (ea030307601_ex10-1img12.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0303076-8k_apimeds.htm · Sequence: 1

false

0001894525

2026-08-19

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

August 19, 2026

Apimeds Pharmaceuticals US, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-42545

85-1099700

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification Number)

100 Matawan Rd, Suite 325

Matawan, New Jersey

07747

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including

area code: (848) 201-5010

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

APUS

NYSE American LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive

Agreement.

August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), entered into an Assignment

and Transfer Agreement of Certain Apitox Rights (the “Assignment Agreement”) with FreeT Inc., a company organized under

the laws of the Republic of Korea (“FreeT”). FreeT is the successor to CNP Roen Co., Ltd., which subsequently changed

its corporate name to Inscobee Co., Ltd. and is currently known as FreeT Inc.

Pursuant

to the Assignment Agreement, FreeT irrevocably assigned, transferred, conveyed and delivered to the Company all of FreeT’s right,

title and interest in and to certain Apitox-related rights (the “Assigned Rights”) that were originally acquired by

CNP Roen Co., Ltd. under an Apitox Rights Transfer Agreement dated June 16, 2015 (the “2015 Agreement”).

The

Assigned Rights include: (i) one hundred percent (100%) of the rights relating to the Apitox market for Korean medicine clinics in the

Republic of Korea; (ii) a twenty-five percent (25%) royalty entitlement on the economic proceeds arising from the development, licensing,

sale or other commercialization of Apitox in the United States; (iii) a twenty-five percent (25%) revenue participation right on the net

proceeds from overseas rights agreements; (iv) the right to receive quarterly information regarding the progress and status of the Apitox

clinical program; (v) the right to receive quarterly information concerning the status and progress of overseas rights transactions involving

Apitox; (vi) certain contractual benefits relating to data and technology for third-party manufacturing or rights agreements; and (vii)

other ancillary contractual rights.

The

Assigned Rights are limited to rights actually held by FreeT as of the effective date and only to the extent legally assignable. The Assignment

Agreement expressly excludes any global rights not held by FreeT, any underlying intellectual property ownership in Apitox, and any indication-specific,

territorial, manufacturing, regulatory or commercialization rights not granted to FreeT.

The

Company has confirmed that the Assigned Rights are free and clear of any claims, encumbrances or obligations associated with any prior

side letter arrangements, including those involving Lokahi Therapeutics Inc.

The

Company assumed only those obligations, if any, that arise after the effective date and are directly related to the lawful exercise of

the Assigned Rights. The Company does not assume any payment obligation, breach, liability, debt, claim or other obligation of FreeT arising

before the effective date under the 2015 Agreement.

FreeT

confirmed its intention to support the continued development, indication expansion and global commercialization of Apitox through the

Company and to use commercially reasonable efforts to facilitate future transactions pursuant to which additional Apitox rights for territories

worldwide outside the United States may be granted to the Company, subject to separate definitive agreements.

The

Assignment Agreement is governed by the laws of the Republic of Korea, with exclusive jurisdiction in the Seoul Central District Court.

The

foregoing summary of the Assignment Agreement does not purport to be a complete description and is qualified in its entirety by reference

to the full text of the Assignment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1

Assignment and Transfer Agreement of Certain Apitox Rights, dated August 19, 2026, by and between Apimeds Pharmaceuticals US, Inc. and FreeT Inc.

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Apimeds Pharmaceuticals US, Inc.

Date: August 21, 2026

By:

/s/ Dr. Vin Menon

Name:

Dr. Vin Menon

Title:

Chief Executive Officer

EX-10.1 — ASSIGNMENT AND TRANSFER AGREEMENT OF CERTAIN APITOX RIGHTS, DATED AUGUST 19, 2026, BY AND BETWEEN APIMEDS PHARMACEUTICALS US, INC. AND FREET INC

EX-10.1

Filename: ea030307601ex10-1.htm · Sequence: 2

Exhibit 10.1

Docusign Envelope ID: BDB7F9F5-66FB-8362-8158-B0DC41C63A0A

GRAPHIC

Filename: ea030307601_ex10-1img1.jpg · Sequence: 3

Binary file (538695 bytes)

Download ea030307601_ex10-1img1.jpg

GRAPHIC

Filename: ea030307601_ex10-1img2.jpg · Sequence: 4

Binary file (508135 bytes)

Download ea030307601_ex10-1img2.jpg

GRAPHIC

Filename: ea030307601_ex10-1img3.jpg · Sequence: 5

Binary file (355274 bytes)

Download ea030307601_ex10-1img3.jpg

GRAPHIC

Filename: ea030307601_ex10-1img4.jpg · Sequence: 6

Binary file (106064 bytes)

Download ea030307601_ex10-1img4.jpg

GRAPHIC

Filename: ea030307601_ex10-1img5.jpg · Sequence: 7

Binary file (559584 bytes)

Download ea030307601_ex10-1img5.jpg

GRAPHIC

Filename: ea030307601_ex10-1img6.jpg · Sequence: 8

Binary file (82874 bytes)

Download ea030307601_ex10-1img6.jpg

GRAPHIC

Filename: ea030307601_ex10-1img7.jpg · Sequence: 9

Binary file (548583 bytes)

Download ea030307601_ex10-1img7.jpg

GRAPHIC

Filename: ea030307601_ex10-1img8.jpg · Sequence: 10

Binary file (509077 bytes)

Download ea030307601_ex10-1img8.jpg

GRAPHIC

Filename: ea030307601_ex10-1img9.jpg · Sequence: 11

Binary file (339840 bytes)

Download ea030307601_ex10-1img9.jpg

GRAPHIC

Filename: ea030307601_ex10-1img10.jpg · Sequence: 12

Binary file (99679 bytes)

Download ea030307601_ex10-1img10.jpg

GRAPHIC

Filename: ea030307601_ex10-1img11.jpg · Sequence: 13

Binary file (564766 bytes)

Download ea030307601_ex10-1img11.jpg

GRAPHIC

Filename: ea030307601_ex10-1img12.jpg · Sequence: 14

Binary file (82091 bytes)

Download ea030307601_ex10-1img12.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 19

v3.26.1

Cover

Aug. 19, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 19, 2026

Entity File Number

001-42545

Entity Registrant Name

Apimeds Pharmaceuticals US, Inc.

Entity Central Index Key

0001894525

Entity Tax Identification Number

85-1099700

Entity Incorporation, State or Country Code

Entity Address, Address Line One

100 Matawan Rd

Entity Address, Address Line Two

Suite 325

Entity Address, City or Town

Matawan

Entity Address, State or Province

Entity Address, Postal Zip Code

07747

City Area Code

848

Local Phone Number

201-5010

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

APUS

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration